SAB Biotherapeutics signs manufacturing deal with Emergent for SAB-142; $36M minimum spend post-FDA approval

SAB Biotherapeutics, Inc.

Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.
Term runs 5 years from FDA approval; minimum aggregate spend of $36 million after approval.
Emergent has exclusive manufacturing rights during term; SAB may seek alternative source in limited cases.
Commercial batch price to be set in amendment within 18 months of anticipated commercial sale.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SAB Biotherapeutics, Inc. entered into Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. valued at minimum aggregate spend following any FDA approval equal to $36 million (effective 2026-04-28).

Action: entry
Agreement: supply
Counterparty: Emergent BioSolutions Canada Inc.
Value: minimum aggregate spend following any FDA approval equal to $36 million
Effective: 2026-04-28

Exact text from the filing

On April 28, 2026 (the “Effective Date”), SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) entered into a Master Manufacturing Services Agreement (the “MSA”) with Emergent BioSolutions Canada Inc. (“Emergent”).

View on SEC.gov

Browse all material agreements →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.